Trump signs order to speed up psychedelic drug research, with Joe Rogan by his side

President Donald Trump signed an executive order Saturday that directs federal health agencies to speed up research and regulatory evaluation of certain psychedelic substances, including ibogaine, for treating mental health conditions like PTSD and depression. The order calls for streamlining clinical trials, reducing bureaucratic hurdles, and expanding access to experimental therapies-particularly for military veterans struggling with trauma.

Standing beside him in the Oval Office was podcaster Joe Rogan, a longtime advocate for psychedelic research. Rogan has spent years discussing ibogaine and other psychedelics on his show, often highlighting anecdotal success stories from veterans. According to sources familiar with the planning, Rogan texted Trump earlier in the week urging action, which helped prompt the signing. The image of the two together-once unlikely allies-underscored how once-fringe ideas are gaining traction in mainstream policy.

The push isn't just coming from podcasters. A growing number of conservative lawmakers and veteran advocacy groups have backed the effort, arguing that traditional treatments haven't done enough to curb rising suicide rates among former service members. Some point to preliminary studies and personal testimonials suggesting ibogaine, a powerful hallucinogen derived from a West African plant, can interrupt addiction and reset emotional patterns-though it's not approved by the FDA and carries risks like heart complications.

Health experts remain cautious. While there's emerging interest in psychedelics for therapy, many warn that rushing the process could endanger patients. "These are not benign substances," said one federal researcher who spoke on background. "We need solid data, not just compelling stories." The order does not legalize the drugs but instructs agencies like the FDA and NIH to prioritize reviews and consider fast-tracking promising candidates.

The political shift is notable. Just a decade ago, psychedelics were largely dismissed in conservative circles as relics of the 1960s counterculture. Now, they're being framed as tools of personal resilience and national healing-especially within veteran communities. Robert F. Kennedy Jr., whose views on alternative medicine have gained influence in certain political quarters, has also voiced support for reevaluating psychedelic therapies.

Still, questions linger about oversight and long-term effects. Critics worry that political momentum could outpace science, particularly if pressure mounts to deliver quick results. The administration insists safety remains a priority, but the order reflects a clear bet on innovation over caution.

For now, the spotlight stays on what happens next: how quickly research moves, how the medical community responds, and whether this moment marks a turning point in how America treats mental health-or a risky leap into unproven territory.